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Chronic hand eczema is frequent among atopic derma-
titis (AD) patients. Due to the multifactorial causes of
hand eczema, careful clinical and allergological exam-
ination is important for classification of the individual
case, and hence for advice, treatment and preventive
measures to be recommended. The importance of
patient information and preventive strategies cannot
be overemphasized.
INTRODUCTION
There is no generally accepted classification system for
hand eczema. The history of previous skin disease often
includes either AD or psoriasis. Clinical examination
shows a typical dermatitis pattern. The majority of cases
can be grouped on morphological grounds: 80–90% are
contact hand eczema type, 5–10% are dyshydrotic
(pompholyx) and about 2% are keratotic hand eczema,
which tend to come late in life and may follow the other
two types of eczema.
CLASSIFICATION OF HAND ECZEMA
Hand eczema is a multifactorial disease and can be
considered as endogenous and/or exogenous in origin.
Endogenous hand eczema can present as AD, pom-
pholyx or keratotic eczema. Exogenous eczema can be
allergic contact dermatitis, irritant contact dermatitis,
contact urticaria or microbial eczema. The classification
of hand eczema in a particular patient may similarly vary
over time depending upon when the patient presents at the
clinic. For example, when the skin is dry it may resemble
atopic eczema, whereas if the patient is working in wet
conditions the presentation may resemble irritant contact
eczema (1). Again, the relative importance of endogenous
and exogenous factors may vary from time to time within
the same patient.
In the case of atopic hand eczema, the absolute
requirements for establishing the diagnosis are not
defined. However, there should be a history of previous
AD. There may also be evidence of mucosal atopy, a
positive skin prick test to standard inhalant allergens
and a family history of atopic diseases.




Exogenous eczema can be:
N allergic contact dermatitis
N irritant contact dermatitis
N contact urticaria
N microbial eczema
TREATMENT OF HAND ECZEMA
The initial step in treating hand eczema effectively is to
obtain a good history of the condition in order to rule
out possible differential diagnoses. Patch tests should be
conducted in patients having hand eczema for more
than 3 months, and the type of hand eczema should be
established as far as possible. It is essential to give
patients information on the disease and to educate them
as to its causes and management on a regular basis.
Diagnostic patch tests should always include the
standard series of allergens and, if appropriate, selected
additional allergens which might be present in the
patient’s working environment and topical agents, skin
care products and gloves. An ‘Allergen Bank’ has been
established in Denmark as a service for dermatologists
in practice, who can order special contact allergens for
testing individual patients (2). With patch tests it is
important to take both early and late readings (days 3
and 5–7 post challenge). Careful interpretation of the
results, particularly their relevance, is needed. Detailed
discussion with the patient is needed to fully ascertain
their exposure to allergens.
Patients who had relevant positive patch tests,
enabling them to reduce exposure to the allergen,
showed significant improvement in both perceived
severity of their hand eczema and in the Dermatology
Life Quality Index 2 months later (3). Patients with
negative patch tests did not show significant improve-
ment. Psychological factors are important in the
condition, in that patients who are highly stressed seem
to cope less well than patients who are less prone to
stress (4).
MEDICAL TREATMENT OF HAND ECZEMA
A paramount feature of treating hand eczema is to
provide information and education to the patient
concerning the condition and its treatment. Amongst
the medical agents used are:
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i) Topical corticosteroids: The topical corticosteroid
treatment regimen of choice cannot be established
from the literature (5). Neither the potency of
corticosteroid preparation recommended nor the
application schedule is established. Treatment
tends to be based on teaching and past experience.
Short-term glucocorticoid treatment compromises
both skin permeability barrier homeostasis and
stratum corneum integrity. For example, clobeta-
sol applied twice daily topically for 3 days results
in delayed barrier recovery and increased trans-
epidermal water loss. In mice, there is decreased
production and secretion of lamellar bodies,
inhibition of lipid synthesis and decreased density
of corneodesmosomes (6). Application of epider-
mal lipids reverses these findings. With these
observations in mind the clinician should be aware
of overusing topical steroids, particularly the more
potent ones. However, a recent study could
confirm that long-term control of hand eczema is
possible in up to 80% of patients, if intermittent,
prophylactic use of topical steroids is employed on
a regular basis (7).
ii) Antimicrobial treatment: The role of Staphy-
lococcus aureus is well established and has been
covered comprehensively by others. Secretion of
staphylococcal superantigens causes potent T-cell
activation and may induce steroid insensitivity (8).
Whilst the relevance of these observations to hand
eczema is not fully established, they do explain the
effect of antibiotic treatment (with corticosteroids,
e.g. FucicortH) in severe hand eczema (9).
iii) Topical immunomodulators: Preliminary studies
indicate that topical immunomodulators may have
a role in the treatment of hand eczema. In an open
non-controlled study involving 13 patients with
hand eczema receiving occlusive pimecrolimus
cream 1% for 3 weeks, there was a good effect
and minimal systemic absorption of the active
component (10). In an observer-blinded crossover
trial involving 16 patients with dyshidrotic hand
eczema given 2 weeks of treatment with either
tacrolimus 0.1% or mometasone fumarate,
Schnopp et al. noted 50% improvement in palmar
but not plantar eczema (11). These results suggest
that rotational treatment might be appropriate.
iv) Potassium permanganate soaks: Potassium per-
manganate soaks are often used in acute exacer-
bation of hand eczema as patients find them
effective in relieving itching and oozing, in spite of
the fact that evidence of effect is limited.
v) Oral immunosuppressive agents: Efficacy of oral
immunosuppressive drugs in hand eczema is not
proven. Cyclosporine is no better than topical
corticosteroids in clinical effect and in improving
aspects of quality of life, and there are no
controlled trials with methotrexate and azathio-
prine (5). In our clinic we use azathioprine in
severe cases of hand eczema, in multi-allergic cases
and in AD. Our view (echoed by others present at
the meeting) is that azathioprine is helpful as
second-line therapy for those patients who can
tolerate it.
vi) Oral retinoids: Etretinate 30 mg daily is known to
be effective in keratotic hand eczema (12) by
reducing symptoms by 50% on average.
vii) Radiation therapy: One placebo-controlled trial
has shown that 3 Gy of grenz rays applied on six
occasions at intervals of 1 week improved chronic
hand eczema 5 and 10 weeks after the start of
treatment compared with the untreated control.
However, due to concern about long-term effects,
radiation therapy cannot be recommended (5, 13).
PUVA and UVB are effective, but not proven to
be more effective than conventional topical
corticosteroids (5).
Some patients with irritant hand eczema apparently fail
to respond, despite theoretically appropriate treatment
and ceasing exposure to proven allergens and irritants.
This could be due to poor compliance. There is,
however, some evidence that autocrine regulation of
TNF-alpha expression through the effect of keratino-
cytes may explain why some irritant hand eczema
continues in spite of protection from the irritant
stimulus (14).
SKIN CARE AND USE OF GLOVES
There is no established procedure for evaluating skin
care products. Whilst multiple repeated short-time
occlusive irritation tests have been developed and
internationally validated, it is unclear whether these
simulate real workplace conditions. Trials of skin care
creams have serious limitations, including omission of a
control group, small study populations or short study
periods.
One 4-week field study among 111 cleaners and
kitchen assistants showed in a crossover design that a
moisturizer (LocobaseH) effectively improved skin bar-
rier function during everyday irritant exposure com-
pared to no treatment (15).
PREVENTIVE THERAPY: EVIDENCE-BASED
SKIN CARE PROGRAMMES
Evidence-based skin care programmes can help prevent
work-related skin problems. In a study involving
auxilliary nurses undergoing practical training, nurses
receiving a skin care programme changed their beha-
viour and had less skin problems than did the control
group (16), and in a large machine industry with 7000
employees in the production line the frequency of
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occupationally related eczema decreased over a 10-year
period simultaneously with increased use of emollients
and moisturizers (17). The components of a typical skin
care programme are shown in Table I (16, 18).
Patients with hand eczema should avoid using alka-
line soaps as these are known to disturb stratum
corneum integrity by activation of serine proteases and
degradation of corneodesmosomes. They also delay skin
barrier recovery by decreasing beta-gluco-cerebrosidase
activity (19). Liquid soaps also present a problem as
patients tend to use too much, so conventional soap bars
are better.
CONCLUSION
Effective management of hand eczema requires a good
doctor–patient relationship. Time must be spent on
discussing the causes, prevention and treatment with
every patient. Educating the patient as to the causes of
hand eczema and its avoidance is particularly important.
Treatment of occupational hand eczema should be
evidence-based, if the evidence exists, and involve
effective drug treatment regimens and skin care pro-
grammes, the three components of which are skin
protection before work, cleansing and the use of
emollients after work.
DISCUSSION
Thestrup-Pedersen; Some years ago a company in
Denmark introduced a health care programme for
workers, because they had hand eczema problems.
Free emollients and advice were given by company
doctors. The incidence of hand eczema fell from around
7% to 2–3% over a 5-year period.
Diepgen; I think we all have similar personal experience,
but controlled clinical trials are lacking. A literature
search showed the lack of controlled trials.
Andersen; I agree, but a suitable trial design is difficult,
as is adequate patient compliance over the long term.
Diepgen; The response criterion is also difficult to decide
upon. Data show a poor correlation between severity
and response scores graded by clinicians and patients.
Quality of life assessment is equally poor, when
compared to clinicians’ outcomes.
Agner; We need a suitable scoring system for hand
eczema. We have in a pilot study found quite a good
correlation between a self-graded score for hand eczema
and that of the clinician.
McFadden; What is your attitude to the use of liquid
soaps and how do you deal with the period after a
response, but before the skin barrier is re-established?
When do you use second-line therapies?
Andersen; Liquid soaps should not be used – too much is
commonly taken; use a soap bar instead. Tell patients to
be careful during the vulnerable period, which can last 6
months. It is difficult if the patient has young children,
where there is a lot of washing required. We have an
interest in Compositae dermatitis, and in suitable
patients we use azathioprine during the plant growing
season. For people with recurrent severe hand eczema
we use azathioprine as third-line therapy.
Agner; In experimental studies you see a hardening of
the skin in 6 weeks after exposure to detergents, but how
this relates to the clinical situation is not known.
Thestrup-Pedersen; You talked about the chronicity of
hand eczema. Is it possible to stop this progression?
Andersen; I believe so. If you get the patient early you
may be able to control this, but I have no evidence.
Agner and Thestrup-Pedersen; We have the same
opinion.
Traulsen; Do you have any views on the skin barrier
after corticosteroid use?
Andersen; We know steroids can cause skin atrophy and
patients say that they are not good for them. This may
be a matter of dose, I advise intermittent use of steroids.
Agner; We do not know for certain if intermittent use is
any better, but no doubt this could be studied.
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